The Medical Letter on Drugs and Therapeutics
December 16, 2019
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Trifarotene (Aklief) - A New Topical Retinoid for Acne
December 16, 2019 (Issue: 1587)The FDA has approved trifarotene 0.005% cream (Aklief – Galderma) for topical treatment of acne vulgaris in patients ≥9 years old. Trifarotene is the fourth topical retinoid to be approved in the US for treatment of acne; tretinoin (Retin-A,...more
- In brief: an over-the-counter retinoid for acne. Med Lett Drugs Ther 2016; 58:126.
- Drugs for acne. Med Lett Drugs Ther 2016; 58:13.
- AL Zaenglein et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74:945.
- A Chien. Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments. J Drugs Dermatol 2018; 17:s51.
- J Aubert et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol 2018; 179:442.
- J Tan et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol 2019; 80:1691.
- U Blume-Peytavi et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol 2019 July 15 (epub).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.